CYP1A1m2 polymorphisms regulate estrogen and interleukin-6 in lung cancer

Molecular Medicine Reports

Volumn 3, Issue 6, 2010, Pages 971-976

  Sreelekha, T T ^a   Rajesh, M ^a   Anil Kumar, V ^a   Madhavan, J ^a   Balaram, P ^b  

^a REGIONAL CANCER CENTRE   (India)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

Author keywords

Cytochrome P 450; Estrogen; Interleukin 6; Lung cancer; Polymorphism

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A1M2; ESTRADIOL; ESTROGEN; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; ESTROGEN SYNTHESIS; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RISK ASSESSMENT;

EID: 78649452120     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2010.352     Document Type: Article

References (33)

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2005 Incidence and Mortality Web-based Report. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention; Washington, DC: National Cancer Institute; 2009. www.cdc.gov/uscs.
2. Sin DD, Cohen SB, Day A, Coxson H and Paré PD: Understanding the biological differences in susceptibility to chronic obstructive pulmonary disease between men and women. Proc Am Thorac Soc 4: 671-674, 2007. (Pubitemid 350291631)
3. Niikawa H, Suzuki T, MiKi Y, et al: Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14: 4417-4426, 2008.
4. Melville K: Estrogen May Fuel Lung Cancer Growth. April 2000. http://www.scienceagogo.com/news/20000302190630data-trunc-sys.shtml.
5. Tsuchiya Y and Nakajima MT: Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227: 115-124, 2005. (Pubitemid 41174580)
6. Lee KM, Kang D, Clapper ML, et al: CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. Cancer Epidemiol Biomarkers Prev 17: 1120-1126, 2008.
7. Sreeja L, Syamala V, Hariharan S, Madhavan J, Sivanandan CD and Ankathil R: Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. J Hum Genet 50: 618-627, 2005. (Pubitemid 41768782)
8. Shaffi SM, Shah MA, Bhat IA, Koul P, Ahmad SN and Siddiqi MA: CYP1A1 polymorphisms and risk of lung cancer in the ethnic Kashmiri population. Asian Pacific J Cancer Prev 10: 651-656, 2009.
9. Wright CM, Larsen JE, Colosimo ML, et al: Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. Eur Respir J 35: 152-159, 2010.
10. Pisani P, Srivatanakul P, Anderson-Moor JR, et al: GSTM1 and CYP1A1 polymorphisms, tobacco, air pollution and lung cancer: a study in rural Thailand. Cancer Epidemiol Biomarkers Prev 15: 667-674, 2006.
11. Schneider J, Bernges U, Philipp M and Woitowitz HJ: GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking. Cancer Lett 208: 65-74, 2004.
12. Zhuo X, Cai L, Xiang Z, Li Q and Zhang X: GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis. J Exp Clin Cancer Res 28: 461-468, 2009.
13. Hodge DR, Hurt EM and Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512, 2005.
14. Pottratz ST, Bellido T, Mocharla H, Crabb D and Manolagas SC: 17 beta-estradiol inhibits expression of human interleukin-6 promoter receptor constructs by a receptor dependent mechanism. J Clin Invest 93: 944-950, 1994. (Pubitemid 2044954)
15. Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning, A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.
16. Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR and Pillai MR: Genetic polymorphism of CYP1 A1, GST M1 and GSTT1 genes in Indian oral cancer. Oral Oncol 37: 593-598, 2001.
17. Brownson RC, Alavanja MC, Hock ET and Loy TS: Passive smoking and lung cancer in nonsmoking women. Am J Public Health 82: 1525-1530, 1992.
18. Samet JM, Brenner D, Brooks AL, et al: Health effects of exposure to radon: BEIR VI. National Academy Press, Washington (DC), 1998.
19. Alavanja MC, Brownson RC and Benichou J: Estimating the effect of dietary fat on the risk of lung cancer in nonsmoking women. Lung Cancer 14 (Suppl 1): 63-74, 1996.
20. Alavanja MC, Brown CC, Swanson C and Brownson RC: Saturated fat intake and lung cancer risk among nonsmoking women in Missouri. J Natl Cancer Inst 85: 1906-1916, 1993.
21. Wu AH, Fontham ET, Reynolds P, et al: Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 141: 1023-1032, 1995.
22. Alavanja MC, Brownson RC, Benichou J, Swanson C and Boice JD Jr: Attributable risk of lung cancer in lifetime nonsmokers and long-term ex-smokers (Missouri, United States). Cancer Causes Control 6: 209-216, 1995.
23. Sellers TA, Potter JD, Bailey-Wilson JE, Rich SS, Rothschild H and Elston RC: Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition. Cancer Res 52 (Suppl 9): 2694-2697, 1992.
24. Mendelson CR, MacDonald PC and Johnston JM: Estrogen binding in human foetal lung tissue cytosol. Endocrinology 106: 368-374, 1980.
25. Prescott E, Bjerg AM, Andersen P, Lange and Vestbo J: Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 10: 822-827, 1997. (Pubitemid 27180193)
26. Kmietowicz Z: Women at double risk of small cell lung cancer. BMJ 317: 1614, 1998.
27. Zang EA and Wynder EL: Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 88: 183-192, 1996.
28. Salgado R, Junius S, Benoy I, et al: Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103: 642-646, 2003.
29. Hong DS, Angelo LS and Kurzrock R: Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110: 1911-1928, 2007.
30. Gao SP, Mark KG, Leslie K, et al: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856, 2007.
31. Metayer C: Cooking oil fumes and risk of lung cancer in women in rural Gansu, China. Lung Cancer 35: 111-117, 2002.
32. Caspar P, Moreira J, Kvitko K, Torres M, Moreira A and Weimer T: CYP1A1, CYP2E1, GSTM1, GSTT1, GSTP1, and TP53 polymorphisms: do they indicate susceptibility to chronic obstructive pulmonary disease and non-small-cell lung cancer? Genet Mol Biol 27: doi: 10.1590/S1415-47572004000200001. 2004.
33. Spivack SD, Fasco MJ, Walker VE and Kaminsky LS: The molecular epidemiology of lung cancer. Crit Rev Toxicol 27: 319-365, 1997.